NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that NASDAQ has halted trading of the Company’s common stock.
Avenue Therapeutics Stock Trading Halted Today
Globe Newswire -
Tue Feb 15, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/NVIDIA%20Corp%20logo%20outside%20building-by%20BING-JHEN_HONG%20via%20iStock.jpg)
/Advanced%20Micro%20Devices%20Inc_%20logo%20on%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)